RELMADA THERAPEUTICS, INC. Income Statement
RLMD|1 years of annual SEC 10-K data (FY2013-FY2013)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data. All figures from audited SEC 10-K filings.
RELMADA THERAPEUTICS, INC. reported $7,941 in revenue and $12,052 in net loss for FY2013. Its profit margin was -151.8% in FY2013.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -2.19 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2013 |
|---|---|
| Revenue | $7.9K |
| Cost of Revenue | $5.8K |
| Gross Profit | $2.1K |
| SG&A Expense | $9.1K |
| Operating Income | -$12.1K |
| Net Income | -$12.1K |
| EPS (Diluted) | $0.00 |
| Shares Outstanding | 16.3M |
| Gross Margin | 27.0% |
| Operating Margin | -151.8% |
| Profit Margin | -151.8% |